StreetInsider.com News Articles

NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

Thu, 22 Oct 2026 08:29:00 -0400

Successful parallel production process maintains consistency while doubling exosome yield without increasing manufacturing time

TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced that it doubled exosome production by successfully operating two bioreactors in parallel, while maintaining the same overall production time, process consistency and comparable exosome quality. The achievement marks an important step in NurExone’s strategy to build scalable exosome manufacturing capabilities through its wholly owned U.S. subsidiary, Exo-Top

NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

Thu, 22 Oct 2026 08:29:00 -0400

Successful parallel production process maintains consistency while doubling exosome yield without increasing manufacturing time

NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

Fri, 09 Oct 2026 16:03:00 -0400

Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate

TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and lead pharmaceutical drug candidate ExoPTEN in optic nerve injury models. The studies were conducted in collaboration with Prof. Ygal Rotenstreich’s team at the Goldschleger Eye Institute at Sheba Medical Center. The new data supports the

NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

Fri, 09 Oct 2026 16:03:00 -0400

Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

Fri, 18 Sep 2026 16:21:00 -0400

TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 22-25, 2026. The conferences will feature participants from across the global life sciences sector, including investors, scientists and representatives from leading pharmaceutical companies.

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

Fri, 18 Sep 2026 16:21:00 -0400

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

Fri, 18 Sep 2026 16:21:00 -0400

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

Fri, 18 Sep 2026 16:21:00 -0400

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as

NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Wed, 16 Sep 2026 16:04:00 -0400

Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1

TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September 15, 2026 (the “Meeting”). Shareholders voted in favour of each resolution put forth at the Meeting.

Annual General and Special Meeting Results

Capitalized terms

NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Wed, 16 Sep 2026 16:04:00 -0400

Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1

Annual General and Special Meeting Results

Capitalized terms

NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

Mon, 14 Sep 2026 16:03:00 -0400

Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets

TORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device company specializing in precision delivery, to evaluate the integration of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations for eye and skin applications.

NurExone’s exosomes are designed to act

NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

Mon, 14 Sep 2026 16:03:00 -0400

Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets

NurExone’s exosomes are designed to act

NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

Mon, 31 Aug 2026 07:33:00 -0400

TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update on its recent activities and upcoming milestones.

The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at

NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

Mon, 31 Aug 2026 07:33:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference